• By ICR Secretariat
  • Posted Thursday, September 12, 2019

Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters


Amgen's never moved faster.

In late August of last year, the first patient enrolled in a small clinical study received treatment with a cancer drug now known as AMG 510. Just over nine months later, Amgen executives were at oncology's premier annual meeting presenting results from the Phase 1 portion of testing.